Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
Policing minister Dame Diana Johnson will write to the Advisory Council on the Misuse of Drugs asking whether its classification should be changed.
Policing minister, Dame Diana Johnson, has written to the Advisory Council on the Misuse of Drugs (ACMD) to commission advice on ketamine and to consider whether it should become a Class A drug.
The US Food and Drug Administration (FDA) has expanded the approval for Johnson & Johnson’s nasal spray Spravato to allow its standalone use in patients with depression, the company said on Jan 21.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback